Alimera sciences, inc. obtains marketing authorization for iluvien in portugal for the treatment of non-infectious posterior uveitis

Alimera sciences, inc. announced that infarmed, the governmental agency that oversees the availability of medical products in portugal, granted marketing authorization on october 1, 2019 for iluvien for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment. alimera will market the product directly to physicians in portugal through its european sales organization. alimera currently sells iluvien in portugal for the treatment of diabetic macular edema (dme). once reimbursement for the new indication is granted, alimera will begin marketing iluvien in portugal for nipu as well.
ALIM Ratings Summary
ALIM Quant Ranking